Loading
A phase 2 trial of Izalontamab brengitecan in non-small-cell lung cancer and small-cell lung cancer, run by Sichuan Baili Pharmaceutical Co., Ltd., now recruiting.
A Study of SI-B003 and BL-B01D1+SI-B003 in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer, Nasopharyngeal Carcinoma and Other Solid Tumors is a phase 2 interventional study registered as NCT05956587 by Sichuan Baili Pharmaceutical Co., Ltd., with 121 participants planned, started 2024-01-29 and due to reach its primary completion in 2026-12. Interventions recorded: BL-B01D1, SI-B003. Conditions listed: Non-small Cell Lung Cancer, Nasopharyngeal Carcinoma. No results are recorded here; the registry entry is the source.
Shares Recurrent and metastatic nasopharyngeal carcinoma, Izalontamab brengitecan, SystImmune / Sichuan Biokin, Nasopharyngeal carcinoma.
Shares Bispecific ADC, Izalontamab brengitecan, SystImmune / Sichuan Biokin, Antibody-drug conjugate (ADC).
Shares Bispecific ADC, Izalontamab brengitecan, SystImmune / Sichuan Biokin, Antibody-drug conjugate (ADC).
Shares Bispecific ADC, Izalontamab brengitecan, SystImmune / Sichuan Biokin, Antibody-drug conjugate (ADC).
Shares Bispecific ADC, Izalontamab brengitecan, SystImmune / Sichuan Biokin, Antibody-drug conjugate (ADC).
Shares Bispecific ADC, Izalontamab brengitecan, SystImmune / Sichuan Biokin, Antibody-drug conjugate (ADC).
Shares Bispecific ADC, Izalontamab brengitecan, SystImmune / Sichuan Biokin, Antibody-drug conjugate (ADC).
Shares Recurrent and metastatic nasopharyngeal carcinoma, Izalontamab brengitecan, SystImmune / Sichuan Biokin, Nasopharyngeal carcinoma.